Compare JPMorgan Chase & Co (JPM) vs Kymera Therapeutics Inc. Common Stock (KYMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Kymera Therapeutics Inc. Common Stock — how do they compare? JPMorgan Chase & Co trades at $338.7 (market cap $890.37B), while Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B). The key difference: JPMorgan Chase & Co is far larger — about 100.4× Kymera Therapeutics Inc. Common Stock's market cap, and JPMorgan Chase & Co pays a 1.97% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Chase & Co for 127 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| JPM | KYMR | |
|---|---|---|
Market Cap | $890.37B | $8.87B |
Volume | 10,236,412 | 779,107 |
Sector | Financials | Health |
52-Week High | $365.18 | $127.31 |
52-Week Low | $282.84 | $55.80 |
Typical Hold Time | 127 Days | 0 Days |
Enterprise Value | $1.40T | $8.26B |
Dividend Yield | 1.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase (JPM) trades at $331.43, down 0.86% on the day, with a bearish technical signal despite strong fundamentals. The company reported mixed Q3 2026 earnings but beat expectations in Q1 and Q2, with revenue growing to $181.85B in 2025. Analyst consensus remains positive with a $373.36 price target, though technical indicators show resistance near $336-339 levels.
JPMorgan offers solid investment potential with strong profitability (33.38% net margin) and attractive valuation (P/E 13.9), but faces headwinds from negative cash flow trends and geopolitical risks highlighted in recent CEO warnings. The stock's current technical weakness suggests near-term consolidation before potential upside toward analyst targets.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →
